A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-671
- Sponsors Merck Sharp & Dohme
- 12 Feb 2018 New trial record
- 08 Feb 2018 Planned end date changed from 7 Jun 2026 to 26 may 2026.
- 08 Feb 2018 Planned Initiation date changed from 9 Mar 2018 to 15 Mar 2018.